<DOC>
	<DOC>NCT00571519</DOC>
	<brief_summary>This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in subjects with type 2 diabetes currently sub-optimally controlled by diet and exercise or with non-thiazolidinedione antihyperglycemic monotherapy. Pioglitazone is used as active comparator. The total duration of a subject's participation will be approximately 30 weeks, including a 2-week placebo lead-in period, a 26-week double-blind treatment period, and a 2-week post-treatment follow-up period. Subjects who complete the randomized portion of the study per protocol may have the opportunity to continue in a long-term extension study of active treatments.</brief_summary>
	<brief_title>Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>type 2 diabetes HbA1c &gt;7% and Less than or equal to 8.5% Cpeptide &gt;0.5 ng/mL current monotherapy with stable dose, nonthiazoleidine for greater than or equal to 3 months prior to screening untreated with any antihyperglycemic agent during 2 months prior to screening type 1 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>